Kiran Mazumdar Shaw speaks at the UNAIDS Health Innovation Exchange Meeting on the sidelines of United Nations General Assembly, held in New York on 25th September 2019. Your Excellencies, Distinguished Ladies and Gentlemen, We have just witnessed the first UN High Level meeting on Universal Health Care on Monday. Governments have a collective moral responsibility … Continue reading Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents/Day for LMICs
US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US
India and the U.S. are witnessing a deepening of ties with a convergence of views on many issues. India is rapidly emerging as a preferred economic and technology partner for the US. India IT and pharma companies have made significant investments and have created jobs in the US. These investments signal a growing economic interdependence … Continue reading US-India Leaders Summit: Paving the Way for Affordable Diabetes & Cancer Care in the US
‘Patient-first, Science Based Regulatory Approaches for Insulins’
Dr. Sundar Ramanan, VP, Global Regulatory Affairs, Biocon, Presented at the U.S. FDA Public Hearing on Increasing Insulins Access Biocon Ltd. was among a handful of biopharmaceutical companies that presented at the U.S. Food and Drug Administration’s (FDA) public hearing “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and … Continue reading ‘Patient-first, Science Based Regulatory Approaches for Insulins’
Biocon’s Insulin Glargine Journey: Crossing a Key Milestone with EC Approval
As a credible, global insulins player, Biocon made sure-footed progress towards its mission of providing a high quality, affordable insulin analog for people with diabetes globally when the European Commission approved the biosimilar Insulin Glargine application submitted by its co-development partner Mylan. Biocon and Mylan are among the first few to receive approval for biosimilar … Continue reading Biocon’s Insulin Glargine Journey: Crossing a Key Milestone with EC Approval
Expanding Oncology Portfolio for the Benefit of Cancer Patients
We added another feather in our cap with the U.S. FDA approval of Fulphila™, biosimilar Pegfilgrastim co-developed with our partner Mylan. Fulphila™ is the first FDA-approved biosimilar Pegfilgrastim and the second biosimilar from Biocon and Mylan’s joint portfolio approved in the U.S. Pegfilgrastim is a long-lasting, pegylated form of recombinant granulocyte colony-stimulating factor that is … Continue reading Expanding Oncology Portfolio for the Benefit of Cancer Patients
Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA
December 2017 was a defining moment in our biosimilars journey when Biocon and partner Mylan became the first companies globally to receive U.S. Food and Drug Administration (FDA) approval for biosimilar Trastuzumab. Ogivri™ (trastuzumab-dkst) was the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S., and it made us the first Indian … Continue reading Biocon’s Trastuzumab Journey: First biosimilar from India to be approved by U.S. FDA
In Conversation with Dr. Arun Chandavarkar, CEO & Jt. MD, on Biocon-Sandoz collaboration for Next Generation Biosimilars
CEO Speaks: On the major milestone for Biocon-Sandoz and how this collaboration will enable Biocon to address the next wave of Global Biosimilar Opportunities!
‘KRABEVA®’s Unique ‘Qual-Check’ Mechanism Ensures Patients Get a Quality-Ascertained Product’: Suresh Subramanian
Mr. Suresh Subramanian, Senior Vice President & Head Branded Formulations, Biocon shares his views on how KRABEVA® can make a significant impact in the biosimilars space.
‘Stand-out’ Quarter for Biocon’s Biologics Business
Biocon reported strong Q2FY17 results. Small Molecules, Biologics and Research Services businesses showed strong growth while it was a stand-out quarter for the Biologics business.
Realizing the Promise of Biosimilars in 2020
Part 2 – The potential financial benefits and better health outcomes from biosimilars use could spur their uptake in health systems globally.